AIM ImmunoTech Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AIM NYSE American 2836 aimimmuno.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AIM ImmunoTech Inc.

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks - Feb 7th, 2025 1:50 pm
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer - Feb 5th, 2025 1:00 pm
AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions - Jan 23rd, 2025 1:50 pm
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS - Jan 22nd, 2025 1:30 pm
AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - Jan 17th, 2025 5:00 pm
AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones - Jan 15th, 2025 2:05 pm
AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - Dec 17th, 2024 9:45 pm
AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting - Dec 17th, 2024 8:10 pm
AIM ImmunoTech Reminds Shareholders to Vote "FOR" All Four Incumbent Board Members on the WHITE Universal Proxy Card - Dec 16th, 2024 1:00 pm
Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board - Dec 14th, 2024 9:54 pm
UPDATE: Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card - Dec 13th, 2024 8:48 pm
AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card "FOR" All Four Incumbent Board Members - Dec 12th, 2024 8:00 pm
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue - Dec 12th, 2024 2:00 pm
Kellner Group Announces Support from Another Former AIM Senior Executive - Dec 12th, 2024 1:16 pm
AIM’s Clinical Strategy Under Incumbent Board Has Totally Failed - Dec 11th, 2024 12:30 pm
Glass Lewis Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell - Dec 10th, 2024 3:20 pm
Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected - Dec 10th, 2024 12:30 pm
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment - Dec 6th, 2024 2:15 pm
Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card - Dec 6th, 2024 1:34 pm
ISS Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan and Dr. William M. Mitchell - Dec 5th, 2024 2:00 pm